CTLA4 gene polymorphism and autoimmunity by Alakhras, Haneen
 1 
 
 
 
 
 
 
 
CTLA4 gene polymorphism and autoimmunity 
 
 
 
By 
Haneen Alakhras 
 
 
Advisors  
Dr . Tamer Essawi  
Prof. Dr. Jan Phillipe  
 
2014  
  
 2 
 
 
 
 
CTLA4 gene polymorphism and autoimmunity 
 
 
By 
Haneen Alakhras 
 
Advisors  
Dr . Tamer Essawi  
Prof. Dr. Jan Phillipe  
 
 
This thesis was submitted in partial fulfillment of the requirements of the master’s degree in 
clinical laboratory sciences from the faculty of graduate studies at Birzeit University, Palestine. 
November / 2014  
 
 
 3 
 
 
CTLA4 gene polymorphism and autoimmunity 
 
 
By 
Haneen Alakhras 
 
This thesis was successfully defended and approved on Thursday 27\11\2014. 
 
Examination committee                                                           Signature    
Tamer Essawi,  PhD (Advisor)                                             
Jan Phillipe,  PhD (Advisor)   
Wael Hammouda, M.D. (External examiner )   
Mohhamad Farraj,  PhD (Internal examiner)  
 
 
 
 
 
 
 
 
 4 
 
Dedication 
 
I would like to dedicate this work to my father Radwan Al-Akhras, my 
mother Rawheya, my brother Mohammad and my sisters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
 
Acknowledgements 
 
 
I would like to acknowledge my advisors Dr. Tamer Essawi, the Dean of the 
Faculty of Nursing Pharmacy and Health professions at Birzeit University, and 
Professor Dr. Jan Philipe from Gent University in Belgium. They provided me 
with guidance, support and all I needed to accomplish this project. 
I would like also to thank Dr. Mohammad Farraj for his support throughout this 
work. Israr Sabri was a big help, I would like to thank him for his efforts.   
 
 
 
 
HRA 
 
 
 
 
 
 
 
 
 
 6 
 
Table of contents 
 
Chapter                                                                                                     page  
 
I- Introduction                                                                                                               1   
 Etiology of autoimmune diseases                2                                                                     
-Intrinsic factors  
i. Genetics 2                                                                                    
ii. Gender 3                                                                                       
iii. Hormones  3                                                                                
iv. Race 3                                                                                          
v. Age 4                                                                                           
-Environmental factors 4                                                                                     
 Classification of autoimmune diseases 5                                                            
-Systemic 5                                                                                                           
-Organ -specific   5                                                                                                
 Involvement of immune system in autoimmune mechanisms 6                          
 Role of innate mechanisms 11                                                                               
 CTLA4 11                                                                                                            
 Genetics of CTLA 4 14                                                                                        
 Genetics of autoimmune diseases 14                                                                   
 Literature review 11                                                                                             
 CTLA 4 genotype correlation to Treg frequency 11                                           
 Hypothesis 22                                                                                                      
 Objectives 22                                                                                                      
Chapter II 
 Materials and methods      21                                                                                    
-Study subjects 21                                                                                               
-Sample collection 22                                                                                         
-DNA extraction 22                                                                                             
 7 
 
-Procedure 23                                                                                                  
I. PCR and single nucleotide polymorphism 24                                    
Chapter III 
 Results 21                                                                                                       
-CT60 mutation 21                                                                                         
-A/G 49 mutation 21                                                                                      
Chapter IV 
 Discussion 31                                                                                                 
References 33                                                                                                            
Annex I                                                                                                                37           
Annex II                                                                                                               39  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
 
 
List of Tables 
 
Table Title Page 
1  
Strategies for maintaining immune system self tolerance ……………….. 
 
1 
2  
Selected mechanisms for self tolerance breakdown in immune diseases … 
 
12 
3  
Distribution of autoimmune disease for patients participating in the study . 
 
21 
4  
Summary of the results obtained for the RFLP-PCR for CT60 and AG49 
for cases and controls …………………………………………………….. 
 
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9 
 
 List of Figures  
 
 
 
Figure Title Page 
 
1 Interaction of genes and the environment in the pathogenesis of 
autoimmune diseases ……………………………………………………….. 
 
5 
2 T cell activation and T cell tolerance ………………………………………. 
 
13 
3 Structure of chromosome 2 and the location of CTLA4 gene on q 33.3 …… 
 
14 
4 Central and peripheral tolerance mechanisms …............................................ 
 
16 
5 Co- stimulatory and co-inhibitory molecules role in T cell activation ……... 
 
11 
6 Agarose gel electrophoresisCT60 ………………………………………….. 25 
7 Agarose gel electrophoresis AG49 ………………………………………… 27 
8 Agaarose gel electrophoresis showing restriction results of CT60mutation   29 
9 Gel electrophoresis of RFLP-PCR for AG49 mutation ……………………. 
 
30 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
 
Abstract 
Autoimmunity is the process where auto-reactive T- lymphocytes or auto-antibodies produced by 
B-cells react against self antigens. The prevalence of autoimmune diseases has been estimated to 
be 3-5% which makes it one of the major health concerns. 
A total of 120 samples were collected from Patients with different autoimmune diseases from 
hospitals and clinics throughout the West Bank and 82 from normal controls. The aims of this 
study were focusing on the presence of two point mutations on the CTLA4 gene; CT60 and 
AG49, and to associate between their presence and susceptibility to autoimmune diseases in the 
Palestinian population living in the West Bank, Palestine.  Both mutations were tested using 
RFLP-PCR on all cases and control samples. 
There was a significant difference in the AG49 point mutation between the controls (29.6%) and 
patients (60%) for the G allele (P<0.05).  Homozygous A allele was clearly much higher in 
controls (70.4%) as compared to patients (40%).  For point mutation in the CT60 allele, there 
was no significant association between the sample tested and autoimmune diseases (P>0.05). 
Results reflect that the G allele doesn’t play a role in susceptibility to autoimmune diseases.  
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 الملخص
 
 .او الاجسام المضادة المصنعة داخل الجسم  Tيحدث خلالها مهاجمة خلايا الجسم من خلاياه الليمفاويةالمناعة الذاتية هي عملية 
 .التي تجعل منها واحدة من المخاوف الصحية الرئيسية .٪  5-3ويقدر انتشار أمراض المناعة الذاتية أن تكون 
ربط بين وجودها و التعرض ن، ل 94GAو  06TC،  4ALTCمن الجين  ن نركز على اثنين من الطفرات نحراسة في هذه الد
 .منطقة الضفة الغربية فلسطين  تحديداللأمراض المناعة الذاتية في 
من اشخاص اتية وعينات على المرضى من مختلف أمراض المناعة الذ RCP- PLFRتم اختبار كل من الطفرات باستخدام 
 .سليمين للمقارنة 
عينة من المرضى الذين يعانون من أمراض المناعة الذاتية المختلفة من المستشفيات والعيادات في أنحاء الضفة  221 جمعنا 
 .عينة  من اشخاص سليمين  21الغربية و 
<  G )P لاليل ل) ٪ 26(والمرضى ) ٪  6.12(  ينات الاشخاص السليمين  بين ع 94GA ان هناك اختلاف كبير في طفرة ك
) ٪24(نة مع المرضى بالمقار) ٪  4.21( فى عينات الاشخاص السليمين اعلى بشكل واضح  متماثل كان A) .52.2
) . 52.2> P( لم يكن هناك ارتباط كبير بين العينة المختبرة و أمراض المناعة الذاتية  ، 06TCفي أليل  طفرة  بخصوص.
 .لعب دورا في التعرض ل أمراض المناعة الذاتية يلا  Gوتعكس النتائج أن أليل 
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Chapter I 
 
Introduction 
The concept of self vs. non-self discrimination was known since 1949 (1).  Autoimmunity or 
breakdown of self tolerance can be defined as imbalance between immunity and self tolerance 
where T-helper cell function excessively increased and T-cell suppression become deficient. In 
other words, autoimmunity is the process where auto-reactive T- lymphocytes or auto-antibodies 
produced by B-cells react against self antigens.  
It may be part of the physiological immune response (natural autoimmunity) or pathologically 
induced, which may lead to development of clinical abnormalities (autoimmune diseases).(2) 
Many different autoimmune diseases can occur due to various factors such as genetic 
predisposition, viral infections, environmental factors, stress, aging, hormones and pregnancy. 
All autoimmune diseases are characterized by the excessive immune response against self-
antigens, leading to chronic inflammation, tissue destruction, and/or dysfunction. Recent 
evidence revealed the presence of more than 60 diseases that are strongly suspected to be of 
autoimmune origin. (2) 
Autoimmune diseases are usually more common in women than men. The prevalence of all 
autoimmune diseases combined is high. The prevalence in the general population has been 
estimated to be 3-5% emphasizing their importance in  public health. Due to  difficulties in 
diagnosing autoimmune diseases,  designing and standardizing epidemiological studies, limited 
data are available, and the prevalence may actually be underestimated.(3) 
 
 
Etiology of Autoimmune Diseases  
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Autoimmune diseases usually occur in families indicating a genetic susceptibility.  Two thirds of 
the affected patients are women which may indicate some additional environmental, stress or 
hormones. Following are the major causes that may individually or combined act in the 
development of autoimmune diseases: 
Intrinsic factors (genetics, hormones, gender, and race)  
 Genetics  
Autoimmune diseases are good examples of multigenic diseases. These genes induce the 
transcription of proteins involved in key pathogenetic pathways, including apoptosis and 
clearance of apoptotic material or immune complexes, function of innate and adaptive immunity, 
production of cytokines, chemokines, or adhesion molecules (4) 
The genetic involvement in autoimmune disease has been investigated. Such investigations have 
reported that identical twins for example will suffer from the same disease. Furthermore, 
emphasis was put on relatives of autoimmune patients are at higher risk of developing the same 
autoimmune disease. It was also observed the predominance of certain autoimmune diseases 
among certain races or ethnic groups (3). 
The genetics of autoimmune diseases does not follow Mendelian genetics and allele segregation 
as seen in autosomal recessive genetic disorders or the presence of single gene mutation as seen 
in cystic fibrosis. The inherited genes involved in autoimmune diseases do not individually lead 
to the development of the disease but in combination may predict the susceptibility of carriers to 
these diseases (3).  
 
 
Gender  
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Studies showed that autoimmune diseases affect females more than males, 65%of autoimmune 
diagnosed patients are females (5). Theories were suggested to explain female susceptibility; one 
theory indicates that women are genetically predisposed to abnormal autoimmune function, 
because the X chromosome may confer susceptibility towards tolerance breakdown.  
Another theory suggests that microchimerism (transfer of cells between mother and fetus during 
pregnancy, twin-to-twin transfer in utero, from organ transplantation, and blood transfusion). 
may play an important role in the immunologic tolerance of the fetal semi-allograft, female 
preponderance may be understood as a consequence of increased allogeneic cell traffic in 
females . In view of increased exposure to cell traffic, women would be expected to pay a higher 
price, reflected in more autoimmunity (6) 
 Hormones  
Research has focused on the relation between sex hormones and autoimmune diseases. Studies 
reported that estrogens promote antibody production-enhancing Th2 response that increases the 
risk towards abnormal autoimmune function (6). This may explain that Sex hormones influence 
the normal differentiation, maturation, and migration of lymphocytes.(7). 
 Race  
Some ethnic groups may be at higher risk for some autoimmune diseases and lower risk for 
others (5).  Studies conducted in the United States showed that autoimmune disease are more 
common among certain ethnic groups as seen that African Americans are at higher risk than 
Caucasians for developing systemic lupus erythematosus and scleroderma. However, the same 
study showed that African Americans are at lower risk for type 1 diabetes and multiple sclerosis.  
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Studies on genetic variations and various susceptibilities in ethnic groups to certain autoimmune 
diseases have  focused on genetic differences that may contribute to variations in disease risk, 
including genes affecting immune response and metabolism(3) 
 
 Age   
Several studies have reported increasing rates of some autoimmune diseases such as  
Type 1 diabetes mellitus  over periods ranging from 10 to 40 years, However, rheumatoid 
arthritis appears to have declined rates during this period.(5)  
Environmental factors (infections, diet, drugs, environmental chemicals) may 
influence induction, development, and progression of autoimmune diseases.(2) 
Environmental exposure may lead to epigenetic regulation via biochemical modifications 
such as acetylation, methylation or other mechanism (4). 
Figure 1 shows the interaction of genes and environmental factors that can lead to 
autoimmune pathogenesis. The role of the environmental factors in autoimmunity is 
summarized in Table 2. 
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Fig. 1. Interaction of genes and the environment in the pathogenesis of autoimmune diseases (4) 
 
It has been reported that Infectious agents may play a role in inducing autoimmunity by a 
mechanism called “molecular mimicry”. This is mainly due to the presence of amino acid 
sequences on these agents that may resemble self antigens. In addition, infectious agents have the 
ability to induce inflammation and release of tissue antigens that can be recognized by the 
immune system as foreign (8). 
 
Classification of autoimmune diseases  
Autoimmune diseases are classified according to the following criteria:  (9) 
 Systemic:  such as systemic lupus erythematosus, or SLE which is mediated by the 
production of autoantibodies which are not tissue specific. 
 Organ-specific:  such as Graves disease which is mediated by the production of 
antibodies against a specific organ or tissue antigens. 
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Involvement of immune system in autoimmune diseases mechanisms  
The main function of the immune system is distinction between self and non-self antigens. This 
process is  well regulated depending on the interaction between Antigen Presenting Cells (APCs) 
and effector T and B cells and products to ensure tolerance to self elements(2). 
Tolerance to self antigens is mainly mediated by the acquired immune system. This system relies 
on the complements of B and T lymphocytes and their membrane- bound antigen specific 
molecules . In addition, the acquired immune system may require the help of certain elements of 
the innate immune system which participate in the pathogenesis of autoimmune diseases (2). 
The acquired immune system is stimulated by signals derived from mononuclear leukocytes, 
particularly lymphocytes. Both spontaneous and induced autoimmune diseases are promoted 
primarily by CD4 positive T-lymphocytes of the  T-helper (Th) class that are especially potent 
by releasing a broad spectrum of cytokines that promote the actions of other immune cells. 
Multiple classes of Th-lymphocytes are involved in this process.  Th1 class acts as a booster to 
immune cell activity; Th2 class stimulates the humoral (antibody) response and the Th17 class 
secretes factors to recruit and stimulate neutrophils (10).These Th-cell phenotypes are activated 
by direct contact with APCs (dendritic cells and occasionally mitogen-stimulated B-cells) that 
express major histocompatability complex (MHC) type II as well as a co-stimulatory molecule 
(B7 [CD80/86). 
Lymphocyte activation occurs in one case only if the T-cell forms an immune synapse with an 
APC simultaneously using three signals: 1- the primary T-cell receptor (TCR) binding to MHC 
II, 2- the T-cell co-stimulatory receptor (CD28) linking  with the APC’s co-stimulatory 
molecule, and 3- APC secreted cytokines interacting with T-cell receptors in a paracrine 
fashion.(2) 
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Stimulation by a single receptor-ligand modality is not sufficient to prime the 
Lymphocyte. For B-cell activation, surface-anchored immunoglobulin (Ig) is required for this 
purpose. In AIDx, autoreactive T- and B-lymphocytes engage in mutually assisted positive 
feedback to be responsible for the disease over time. 
The main defect in autoimmune diseases is the loss of self-tolerance, which renders immune 
cells unable to distinguish between ‘‘self’’ and ‘‘non-self’’ antigens. In this regard, the auto-
reactive immune system is functioning ‘‘within normal limits’’ to eliminate threats—except for 
its unfortunate choice of target (2). The strategies for maintaining immune system self-tolerance 
are shown in Table 1. 
 The three main cell-oriented means for preventing autoimmunity are deletion (removal), 
anergy(relaxation), and suppression (restraint). Deletion, involves irreversible pruning of self-
reactive T-cells (11). This process of ‘‘central tolerance’’ (occurring in a core immune organ) 
occurs mainly in the thymus, the primary lymphoid organ for lymphocyte production. In the 
thymic cortex, naive lymphocytes (Th0 class) that learn during development to ignore self 
elements as potential targets are positively selected for continued survival, while T-cell 
precursors that exhibit any affinity for self-antigens are eliminated via apoptosis. The survivor 
cells migrate to the thymic medulla where they are exposed to self-antigens in the presence of 
MHC type I receptors (present on most body cells as a demonstration of ‘‘self’’ status) but not 
MHC type II receptors (the form on APCs) or co-stimulatory molecules. Any T-cells that will 
bind self-antigens with high affinity in the absence of MHC type II and a co-stimulatory signal 
are negatively selected and diverted into an additional round of TCR-mediated apoptosis. 
Together, these two rounds of programmed cell death confer central tolerance. If needed, 
additional apoptosis is undertaken in secondary lymphoid organs. The programmed cell death 
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responsible for this central tolerance is controlled by interactions between Fas and Fas ligand. 
The absence of these molecules results in reduced pruning of auto-reactive T-cells during 
development, which promotes systemic autoimmunity. The mechanisms for self-tolerance 
breakdown in autoimmune diseases due to lymphocyte lapses are described in Table 2. 
The second cell-based alternative for preventing autoimmunity is anergy. The main means by 
which T-cell anergy is induced is for an APC to present a self-antigen as a target in the absence 
of a co-stimulatory signal .The final cell-based mechanism is clonal suppression, where anti-self 
responses are quenched by factors derived from other leukocytes (CD4 CD25 regulatory T-cells 
[Treg] or CD8 suppressor [Ts] cells). This repression may be mediated by cytokines with 
negative feedback activity (transforming growth factor-b [TGF-b]; by protein cross-linking to 
neutralize surface receptors with affinity for a given antigen, or by the genesis of anti-auto-
antibodies that recognize the antigen receptors on autoreactive lymphocytes. Xenobiotics can 
interfere with T-cell suppression by modifying the cytokine profile produced by newly recruited 
leukocytes (2). 
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TABLE 1. Strategies for maintaining immune system self-tolerance (2). 
 
Strategy Mechanism Location 
Central 
 
Central suppression 
Pre-activation deletion 
 
Primary lymphoid organs 
Peripheral 
Antigen sequestration 
 
Anergy (clonal) 
 
Deletion (clonal) 
Physical exclusion of 
immune effector cells 
Induced 
unresponsiveness via 
insufficient co-
stimulation 
Extirpation of 
autoreactive 
lymphocytes 
 
Peripheral organs 
 
Secondary lymphoid 
organs 
 
Secondary lymphoid 
organs 
Suppression (clonal)  
 
Repression of 
autoreactive 
lymphocytes by treg-
cells  
Secondary lymphoid 
organs 
Sites of inflammation 
Cytokine substitution  Alternative 
differentiation to an 
anti-inflammatory 
phenotype  
Secondary lymphoid 
organs 
Sites of inflammation 
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TABLE2.Selected mechanisms for self-tolerance breakdown in autoimmune diseases.(2) 
Strategy Mechanism 
Environmental effects 
Hormonal balance 
 
Stress 
 
 
Xenobiotic exposure 
 
Gender-linked (hypothalamic-pituitary-
gonadal) endocrine effects 
Mental/psychological-based (cortical 
perception  hypothalamic-pituitary-adrenal 
endocrine effects) 
Multiple (mainly altered receptor-mediated 
signaling and molecular cross-linking) 
Fresh foes 
Altered antigens 
 
Molecular mimicry 
 
Unmasking 
 
Self-antigen alteration by attachment of a 
hapten (chemical or metal) to make a neo-
antigen 
Structural/chemical resemblance of self-
antigens to foreign (especially microbial) 
antigens 
Exposure of previously sequestered self-
molecules 
Genetic predisposition 
Antigen-presenting cell (APC) 
haplotype 
T-cell receptor (TCR) haplotype 
 
Certain major histocompatability complex 
(MHC) II variants enhance autoreactivity 
Certain TCR versions promote 
autoimmunity 
Lymphocyte lapses 
 
Cytokine profile 
 
Forbidden clone 
 
 
Hyperactivity 
 
Polyclonal activation 
 
 
Premature senescence 
 
Heightened production of lymphocyte 
clones with a pro-inflammatory phenotype 
Loss of antigen-specific T-suppressor 
lymphocytes permits activation of their 
autoreactive Th-targets 
Excessive function and/or numbers of Th-
lymphocytes 
Pathogen-induced mitogenesis of 
autoreactive B-cells, which can then 
stimulate autoreactive T-cells 
Accelerated loss of telomeres 
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Role of innate immune mechanisms  
Autoimmunity is often considered to be an acquired response, but innate immune cells play 
important roles in moderating self-tolerance. Activated dendritic cells autoreactive T cells. 
Natural killer T (NKT) lymphocytes, suppresses or exacerbate autoimmunity depending on a 
constellation of animal-specific factors. While they have potent immune -modulatory properties, 
NKT cells are not participated in the adaptive immune response. 
In the innate immune system, three endosomal Toll-like receptors (TLR) considered to be major 
participants in some autoimmune diseases. These molecules are highly conserved across species, 
have evolved as receptors to recognize specific forms of microbial (viral) nucleic acid: TLR-3 
for double-stranded (ds) RNA, TLR-7 for single-stranded RNA, and TLR-9 for ds DNA. Binding 
of the appropriate nucleotides induces a pro-inflammatory signal. Unluckily, these TLR have 
also been shown to recognize certain human antigens. The expression patterns for these three 
TLR are often cell type–specific; B-cells bear TLR-7 and TLR- 9, dendritic cells binds either 
TLR-3 alone or both TLR-7 and TLR-9, and fibroblasts carry only TLR-3. These TLRs are 
thought to involve in autoimmune diseases by directing the cells that express them to attack self-
molecules and enhance their expression of pro inflammatory cytokines. In addition, they can 
induce initial B-cell activation (especially TLR-9) in the absence of T-cell support, so that B-cell 
clones break tolerance first. Activated B-cells then in turn activate naive T-cells, which is 
necessary for initiation of developed autoimmune diseases (2). 
CTLA-4 
CTLA4 gene was identified in 1991as a second receptor for the T cell Co-stimulation ligand B7.  
The specific function of this important gene was not clarified until 1995 when it was confirmed 
to inhibit T cell activation (12).  
 23 
 
Activation of T-cell is the main event in the organization of effective cellular and humoral 
immune responses. Activated T cells are essential for provision of T-cell help, promoting the 
development of high-affinity antibody production and the generation of cytotoxic T-cell 
responses. That leads to the fact that, defects in proteins required for T-cell activation give rise to 
significant infectious pathology and malignancies. While the Defects in proteins involved in 
regulating activated T-cell therefore tend to lead to autoimmunity (13). So the major challenge 
faces the regulating of T cell responses is to provide enough reactive T cells against foreign 
antigens while keeping T-cells unresponsive towards self-antigens and that cannot be done 
without special mechanisms for self –tolerance . 
In the thymus large numbers of potentially `self-reactive' T cells are eliminated during negative 
selection in a process termed central tolerance. However, the process of positive selection that 
permits the expansion of T cells with low avidity for self major histocompatibility complex 
(MHC) interactions must also lead to a degree of self-reactivity which is presumably tolerable in 
peripheral T cells. A number of proteins have been identified that may serve the function of 
`quality controlling' peripheral T-cell activation. In this study we will focus on one of those 
proteins, CTLA-4 and its role in autoimmunity. 
Cytotoxic T lymphocyte antigen-4 (CTLA-4) or CD152 is a trans membrane protein member of 
the immunoglobulin gene superfamily containing a single extracellular `V-like' domain , a 
transmembrane domain, and a cytoplasmic tail. Levels of CTLA-4 expression in most resting T 
cells are extremely low (or probably absent), and predominantly appears following T-cell 
activation. The T cell attack can be turned on by stimulating the CD28 receptor on the T cell. 
The T cell attack can be turned off by stimulating the CTLA4 receptor, which acts as an "off" 
switch. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to 
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CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 
transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. 
Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T 
cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an 
inhibitory receptor for B7 molecules (13). T cell activation and T cell tolerance is shown in 
Figure 2.  
 
 
 
Fig 2: T cell activation and T cell tolerance (14). 
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Genetics of CTLA-4  
CTLA-4 gene belongs to the immunoglobulin super family. It encodes the protein which inhibits 
the T cells activation.  There are three domains to the CTLA-4 protein,   V domain, a 
transmembrane domain, and a cytoplasmic tail. There are two different forms of this protein due 
to alternative transcriptional splice. The homodimer which is a membrane-bound isoform 
interconnected by a disulfide bridge and the monomer which is the soluble isoform.  The 
structure of chromosome 2 and the specific position of the CTLA4 gene is shown in Figure 3. 
The protein is 223 amino acids and a molecular weight of 24656 Da.  The exact position of the 
gene on chromosome 2 is located between start: 204,732,509 bp from pter    End: 
204,738,683 bp  from pterSize:6,175 bases     Orientation:plus strand (15) 
 
 
Fig 3. Structure of chromosome 2 and the location of CTLA4 gene on q33.3  (15). 
 
Genetics of autoimmune diseases 
Most of autoimmune diseases may be described as genetic abnormalities in thymic selection. 
Quantitative differences in the expression of the selecting self- antigens and the responsiveness 
of the thymocytes to these antigens can have a major effect on the selection process. Defective 
thymic deletion can be caused by reduced or altered expression of MHC molecules. Thymocytes, 
like mature T cells, require MHC molecules for presentation of (self) antigens to the TCR. If the 
relevant MHC molecule is absent or expressed at a low level in the thymus, thymocytes will not 
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be activated and will not undergo apoptosis. Indeed, this process is sensitive to the level of MHC 
molecule expression, and to the specific MHC alleles which are expressed in the thymus. This is 
the major mechanism by which HLA molecules regulate the peripheral T-cell repertoire and 
overall T-cell immune responsiveness (16). 
Inadequate expression of self- antigens in the thymus can also cause or predispose to 
autoimmune disease. Large number of organ-specific self- antigens is expressed in the thymus. 
The absence of this expression can result in an escape from thymic deletion and the release of 
self-reactive T cells into the periphery.(16) 
Figure 4 explains the selection process starting from bone marrow to thymus ending in 
peripheral.  
Genetic defects in TReg cell functions demonstrated by X- linked recessive disorder IPEX 
(immune dysregulation, poly-endocrinopathy, enteropathy, X-linked syndrome) and is caused by 
mutations in FOXP3. 
TReg cells are totally dependent on IL2 for its proliferation and function , which means any lack 
if IL2 or its receptors can lead to autoimmunity . 
The activation of peripheral T cells is also controlled by genetic defects in T-cell co-stimulatory 
molecules located on the surface of T-cells , and work as a modulator for the e activation of T- 
cells through the TCR(16). 
These co-stimulatory molecules are CD28, the inducible T-cell co-stimulator (ICOS) and the 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4),these are members of the 
immunoglobulin super family ,expressed on T cells and bind homologous ligands on APCs.s. 
CD28 and ICOS provide positive signals while CTLA4 generally work as a negative regulator of 
T-cell activation. 
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Figure 4 Central and peripheral tolerance mechanisms( 16) 
 
T cells are activated through stimulation of the T-cell receptor (TCR). Co-stimulatory and co-
inhibitory molecules on the T-cell surface role, and regulate the degree of activation as well as 
the development of peripheral T-cell tolerance. 
 28 
 
 
Figure 5  Co-stimulatory and co-inhibitory molecules role in T-cell activation. (16) 
 
CD28 and ICOS are activating receptors that bind members of the B7 family of ligands on 
APCs. CTLA4 is inhibitory on most T cells except regulatory T cells, and, like CD28, can bind 
CD80 and CD86, but with varying affinities.  That leads to cross competition for CD28 co-
stimulation. The programmed cell death 1 (PD1) protein is also inhibitory for T-cell activation, 
and can bind two related ligands, PDL1 and PDL2.(16) 
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Literature review  
 Paul Ehrlich in 1901, was the first scientist to introduce the concept of immunological self/non-
self discrimination. He enunciated his misinterpreted doctrine of horror autotoxicosus, where he 
used this expression to refer to the extremely dangerous situation which may result from the 
formation of autotoxins or autoantibodies. After  some  experiments on animal models ,in which 
he tried to immunize animals with self and non self red blood cells, he came up with a 
conclusion that it’s impossible to form antibodies against self antigens and that was proven later 
to be misinterpretation(17)   . 
Later in 1904, Donath and Landsteiner discovered the first known autoantibody which is now 
carrying their names. This autoantibody was found to cause haemoglobinuria a frigore which 
were recurrently seen in syphilis patients. This autohemolysin is not only able to react with 
human red blood cells from different individuals, but also with those of the patient himself, both 
in vitro and in vivo. 
During 1900 to 1915, immunologists continued their efforts to induce anti-tissue antibodies, but 
rarely could they relate those antibodies with any accompanying disease (17). 
In 1933,  Rivers et al., published a group of studies on the induction of neurological diseases in 
experimental animals through immunization with nervous tissue broths or extracts, which is 
known now as experimental autoimmune encephalomyelitis (AEA), and considered as the model 
for the study of some human demyelinating diseases such as multiple sclerosis and post 
vaccination encephalitides. 
In 1945,  the use of adjuvants came in use to enhance experimental induction of autoimmune 
diseases, which led to the recognition of ‘lupus mice’. This has been followed in unexpected 
discoveries in clinical investigation on important human diseases(18). 
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By 1953,  Witebsky collected adequate data for representing the experimental production of 
thyroiditis in rabbits injected with thyroid tissue, he was unable to admit the validity of his own 
experiments, and spent three years searching for the errors he thought he had made. 
Unfortunately, he tried to explain the presence of errors rather than publish the results of his 
brilliant investigations. Later in 1965, autoimmunity was accepted as real and a wide range of 
autoimmune diseases became recognized in the 20th Century Medicine.( 18) 
 
CTLA4 genotype correlation to Treg frequency  
The A allele of CT60 is located in the 3’ untranslated region of CTLA4 , it was considered to be 
single nucleotide polymorphism. Previous  studies found that homozygosity  of this A allele is 
associated with decreased risk of autoimmune diseases , as the CT60 A\A genotype found to be 
associated with elevated level of Treg frequency in blood by 30-40%(19) 
Heterozygosity of CT60A\G allele found to be associated with intermediate risk of autoimmune 
diseases while Treg frequency didn’t have big difference than homozygous CT60 G\G allele 
really. 
Meanwhile there was no approved correlation between AG49 polymorphism which located in 
exon 1 with Treg frequency in peripheral blood.(19) 
Homozygosity  for A allele in both CT60 and AG49 polymorphisms found to be in related 
disequilibrium that means all cases who was homozygous for A allele for CT60 was also 
homozygous for  A allele for AG 49 , reverse is not true .(19) 
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Hypothesis 
Single nucleotide polymorphisms (SNPs) on the CTLA4 gene increase the susceptibility to 
autoimmune diseases. 
 
Objectives  
The aims of this study are: 
1. Determine the presence of the most commonly encountered SNPs in the CTLA 4, 
specifically; A/G 49 and C/T 60 by polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP)  
2. Determine the presence of significant association between CTLA4-SNPs and 
susceptibility to autoimmune diseases in Palestinian population living in the West 
Bank. 
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Chapter II 
Materials and methods 
 
Study subjects 
A total of 120 samples were collected from Patients with different autoimmune disease and 82 
normal controls from hospitals and clinics throughout the West Bank. The population size was 
limited to the known available patients with autoimmune diseases treated in hospitals and clinics 
in the West Bank, Palestine.  
Details on the type of autoimmune diseases for the selected patients are shown in Table 3 below. 
 
Autoimmune disease Number of 
patients 
Rheumatoid arthritis  74 
Autoimmune hepatitis  1 
Crohn’s disease  3 
Behcet’s disease  3 
Systemic lupus erythematosus (SLE) 12 
Mixed connective tissue disease  1 
Scleroderma  3 
Spondylarthritis 6 
Diabetes type І 17 
 120 
 
Table 3: Distribution of autoimmune diseases for patients participating in the study. 
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The guidelines of the Central Ethical Review Committee at Birzeit University were followed. 
The project and potential risks were explained to each subject prior to obtaining his/her oral 
consent to participate. Participation was the free choice of each participant. A questionnaire was 
filled by each participant containing information related to clinical history and demographic data 
such as: Age, Sex and Family history for specific autoimmune diseases of the participant. Other 
autoimmune diseases inherited in the family. A copy of the questionnaire is included in Annex 1. 
 
Sample Collection 
Whole blood was collected from each participant following aseptic techniques in EDTA tubes 
stored at -20
o
 C.  DNA was extracted using the salting out method according to (16); the purity 
and quality of the isolated DNA was checked on 1.5% agarose gel electrophesresis and viewed 
on the Gel-Doc system (BioRad, USA). 
 
DNA extraction 
DNA was isolated from whole blood using the salting out method. Details of the procedure are 
summarized below:  
I. Buffers 
All buffers are prepared and sterilized before storage. Buffer A was autoclaved prior to addition 
of Triton-X-100. Sterilization by filtration was occasionally used instead of autoclaving because 
it is recommended.  
1. Buffer A (Red blood cell lysis buffer) 
0.32 M sucrose 
10 mM Tris HCl 
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5 mM MgCl2 
0.75% Triton-X-100 
Deionized water 
Adjust pH to 7.6 
 
2. Buffer B (Proteinase K buffer)  
20 mM Tris-HCl 
4 mM Na2EDTA 
100 mM NaCl 
Deionized water 
Adjust pH to 7.4 
 
Procedure 
One volume of blood (1 ml) of whole  blood was mixed with 2 volumes (2 ml) of ice cold buffer 
A, mixed gently by inverting the tube 6-8 times and left on ice for 2-3 minutes. The mixture was 
then centrif`uged for 15 minutes at 3500 rpm at 4
o
C. The supernatant was discarded into a 
container with 2.5% bleach solution. The pellet was then suspended  pellet in 2 ml of buffer A 
and 6 ml of water, vortexed briefly and centrifuged  at 3500 rpm for 15 minutes at 4
o
C. This lysis 
step can be repeated until a white to cream pellet is obtained(20).  
An amount of 5 ml of Buffer B and 500 µl of 10% SDS was added to the pellet, vortexed 
vigorously for 30-60 seconds followed by adding 50 µl of freshly made and cooled Proteinase K 
solution (20mg/ml). Ice cold Proteinase K solution should be made fresh prior to use. The tubes 
were then incubated for two hours at 55
o
C in a water bath followed by cooling to room 
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temperature or placing them for 2-3 minutes on ice.  Salting out of all cellular components was 
sedimented by adding 4 ml of 5.3 M NaCl solution. After gentle vortexing for 15 seconds, the 
tubes were centrifuged at 4500 rpm for 15-20 minutes at 4
o
C. Finally, the  off supernatant was 
carefully removed and placed in a sterile microcentrifuge tube. An equal volume of ice cold 
isopropanol was then added, the tube gently inverted 5-6 times to precipitate DNA. The tube was 
then placed in the freezer at -20
o
 C overnight followed by centrifugation at 4, 000 rpms for 20 
minutes. The supernatant was then carefully removed, the pellet is washed twice with ml of 70% 
ethanol and allowed to dry.  The pellet was then suspend in 300-400 µl of Tris HCl,  pH 8.and 
Left to dissolve overnight at 37
o
 C(20). Isolated DNA was stored at -20
o
 C for subsequent PCR 
and restriction (PCR-RFLP).  
 
PCR and Single Nucleotide polymorphism  
CT60 Polymorphism  
A total of 120 cases and 82 controls were analyzed in this study. PCR was conducted as follows:  
The CT60 SNP was determined by PCR-RFLP.  The primers used in this step are forward: 5’- 
CTTCATGAGTCAGCTTTGCACCAGC-3’and reverse: 5’- 
AGCTGAGAAAGCAGGCGGTAAGAAA-3’(21).  
The PCR reaction was carried out in 25 ul volumes consisted of 12.5 ul master mix 2x (source), 
0.4 ul of each primer, 3.5 ul DNA templates and 8.2 ul sterile dH2O. The PCR program was as 
follows: initial denaturation for 6 min at 95°C; followed by  40 cycles of denaturation for 45 sec 
at 95°C; annealing for 45 sec at 60 °C; and elongation for 45 sec at 72°C ,followed by a final 
extension of 5 min at 72°C. The PCR product for the samples was placed on 2% agarose 
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containing 1uM ethidium bromide and compared for their specific size with 100 bp DNA ladder 
(gene direx 100 bp ladder RTU). 
To detect the presence of SNP, 5 ul of the 200-bp PCR product was incubated with 5 units of 
HpyCH4 IV restriction edonuclease for 1 hr at 37°C. The restriction enzyme will cut the PCR 
product in the following manner: 
1. No cut will show a 200 bp band in the gel. 
2. Two bands of 100 bp and 200 bp indicate a heterozygous mutation. 
3. One band of 100 bp indicates a homozygous mutation. 
These results are shown in Figure 6 
 
  
 
Figure 6: Agarose gel electrophoresis showing lane 1: 100 bp ladder, lanes 2,3,6 and 7 
normal, 4 and 8 heterzygous, lane 5 homozygous. 
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A/G 49 Polymorphism  
A total of 120 cases and 82 controls were analyzed in  this study. PCR was conducted as follows: 
The A/G 49 SNP was determined by PCR-RFLP.  The primers used in this step are forward: 5’- 
AAGGCTCAGCTGAACCTGGT-3’; reverse: 5’- CTGCTGAAACAAATGAAACCC-3’ 
(22)The PCR reaction was carried out in 25 ul volumes consisted of 12.5 ul master mix 2x 
(source ), 0.4 ul of each primer, 3.5 ul DNA template and 8.2 ul sterile dH2O. The PCR program 
was as follows: initial denaturation for 7 min at 95°C; followed by  40 cycles of denaturation for 
30 sec at 95°C; annealing for 45 sec at 57 °C; and elongation for 45 sec at 72°C ,followed by a 
final extension of 5 min at 72°C. The PCR product for the samples was placed on 2% agarose 
containing 1uM ethidium bromide and compared for their specific size with 100 bp DNA ladder 
(gene direx 50 bp ladder RTU). 
To detect the presence of SNP, 5 ul of the 152 bp PCR product was incubated with 5 units of 
BstEII restriction edonuclease for 1 hr at 37°C(22). The restriction enzyme will cut the PCR 
product in the following manner: 
1. No cut, will show a 152 bp band indicating polymorphism. 
2. one band of 130 bp indicates a normal allele. 
These results are shown in Figure 7 
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Figure 7: Agarose gel electrophoresis showing restriction results of A/G 49 mutation, lane 
1: 50 bp ladder, lanes 2, 152 bp, lane 3: 130 bp. 
 
*All used reagents were prepared manually in Berziet University lab. 
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Chapter III 
Results 
 
This project was conducted on 120 patients with autoimmune disease and 81 normal controls. 
Whole blood was aseptically collected and DNA was purified. The quality of the isolated DNA 
was checked on 1.5% agarose gel electrophoresis. PCR was then performed using primers  to 
detect mutations on the CTLA4 gene at CT60 and AG49.  The results obtained are summarized 
in Table4 
 
Sample CT60 polymorphism AG49 polymorphism 
 A/A  
Normal (%) 
A/G  
Carrier (%) 
G/G  
Disease (%) 
A/A 
Normal (%) 
G/G 
Disease (%) 
Patients 29 (24.2% ) 65 (54.2) 26 (21.6) 48 (40%) 72 (60%) 
Controls 19 (23.2) 41 (50.6) 22 (27.2) 58 (70.7%) 24 (29.6%) 
 
Table 4: Summary of the results obtained for the RFLP-PCR for CT60 and AG49 for cases 
and controls. 
 
1.  CT60 mutation  
RFLP-PCR was used to determine the presence of the mutation CT60 on the CTLA4 gene that 
can trigger autoimmunity in cases as compared to controls. Restrictions of the PCR products can 
give 3 fragments of different sizes depending on the allelic combinations that may be present. 
These fragments were resolved on agarose gel electrophoresis. The three allelic combinations are 
formed from the normal A allele and the abnormal or mutated G allele. The results of the RFLP 
for this mutation are shown in Figure 8.  
Our results showed that 21.6% (26/120) of the patients carried two mutated alleles G/G , 24.2% 
(29/120) carried the wild type or normal  A/A genotype and 54.2% (65/120) were carriers A/G.  
 40 
 
Allelic combinations for the control group were 27.2% (22/81) G/G, 22.2% (18/81) were A/A 
and 50.6% (41/81) were A/G. There was no significant difference (P>0.05) between the cases 
and controls. 
 
 Figure8:  Gel electrophoresis of  RFLP-PCR for the CT60 mutation. 
 Lane 1: 100 bp ladder, lanes 2, 3, 6 and 7: normal (A/A) alleles ,  
 lanes 4 and 8 mutated (A/G) allele, lane 5 double mutation (G/G) allele  
 
2. A/G 49 mutation  
RFLP-PCR was also used to investigate the role of the A/G 49 mutation on the CTLA4 gene in 
triggering autoimmunity.  Two types of allelic combinations of different sizes with A/A or A/G 
genotypes were resolved by agarose gel electrophoresis. Our results showed that 60% (72/120) 
of patients carried the mutated genotype G/G while 40% (48/120) carried normal A/A allelic 
combination.  As for the controls, 29% (24/81) had the G/G genotype while 70.4% carried the 
normal A/A alleles. There was significant difference between the cases and the controls 
(P<0.05). The results of the RFLP for this mutation are shown in Figure 9. 
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 Figure 9:  Gel electrophoresis of  RFLP-PCR for the AG49 mutation. 
 Lane 5, 100 bp ladder, lanes 1 and 4 are 152 bp  (mutated G/G alleles). 
 Lanes 2, 3, 6 ,7 and 8  normal (A/A) alleles.  
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Chapter 4 
 
Discussion 
 
The aim of this study was to determine the presence of association between two mutations on the 
CTLA4 gene; A/G49 and C/T 60; and susceptibility to autoimmune diseases among Palestinian 
patients living in the West Bank. 
For A/G49 alleles, we detected only two homozygous alleles, A/A and G/G. Statistical analysis 
for our data showed a significant difference between the controls (29.6%) and patients (60%) for 
the G allele (P<0.05). Several studies has been conducted to determine the presence of 
association between the homozygous G allele and susceptibility to autoimmune diseases. An 
association between several autoimmune diseases such as Grave’s disease, Hashimoto’s 
thyroiditis, multiple sclerosis and Type I diabetes mellitus, have been associated with the G allele 
(23). An association has been established between polymorphism of the CTLA4 gene, 
specifically the G allele at position 49 and Rheumatoid arthritis (24).  These findings agree and 
confirm the results of this study since most of the sample collected for this study has been 
obtained from Rheumatoid arthritis patients. It has been reported that G allele polymorphism 
affects cell surface expression of CTLA4 in response to T cell activation (25).  Another 
interpretation for the significant association between the G allele and autoimmunity is the 
impaired control of T cells proliferation (26).   However,  the homozygous A allele was clearly 
much higher in controls (70.4%) as compared to patients (40%). This may indicate that the A 
allele is associated with decreased risk of susceptibility to autoimmune diseases. Furthermore, 
the  heterozygous A/G allele was more common among controls than patients (26)  emphasizing 
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the protective role associated the A allele against autoimmune diseases. In this study, we used 
RFLP-PCR technique with restriction enzymes that can only detect homozygous A and G alleles.  
For C/T60 polymorphism, we did not find significant association between the sample tested and 
autoimmune diseases (P>0.05). We determined polymorphism in patients and controls for the 3 
alleles; AA, GG, AG. Our results as shown in Table 4 reflect that the G allele doesn’t play a role 
in susceptibility to autoimmune diseases. It has been reported among Taiwanese patients that the 
G/G allele is the most prevalent (21). This may indicate the presence of geographical distribution 
of the CTLA4 gene polymorphism. Interestingly, it has been reported that decreased CT60 
polymorphism has been associated with  risk of Rheumatoid arthritis (24) and slightly increased 
risk of coeliac disease among the Dutch population (23). 
The outcome of this study may contribute to better and faster diagnosis of autoimmune diseases. 
However, not all alleles of the CTLA4 gene are useful for this purpose. Our results indicated the 
presence of significant difference between cases and controls for the A/G49 allele. In addition, 
the carriers of this allele have an increased probability of developing Rheumatoid arthritis while 
the carriers of the other allele C/T60 have decreased risk of this condition. Therefore, testing the 
presence of these two alleles my complement the diagnostic procedures of autoimmune diseases 
on one hand and provide valuable information to the physician on the other. Furthermore, it may 
guide the treating physician on the best way to treat the patient or not.   
We feel this study has been limited to only two alleles of the CTLA4 gene. Although this are 
important alleles that contribute to the development of autoimmune diseases, we feel it is also 
important to investigate more alleles on this important gene that may give a better picture of the 
genetics and pathogenesis of autoimmune diseases. 
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ANNEXES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  84
 
 I xennA
 
 ytinummiotua dna msihpromylop eneg 4ALTC
 الاستعداد الجيني لامراض المناعة الذاتية 
 
كافة المعلومات الواردة فى الاستبيان ستستعمل لغرض الدراسة فقط و سيتم التعامل معها بمنتهى المهنية و 
  .السرية 
 
 
 
 
بحثية و عدم ممانعتى لاستخدام  اقر انا الموقع ادناه بموافقتى التامة بالمشاركة فى هذة الدراسة لاغراض
  .عينتى او معلوماتى لاغراض هذا البحث 
 
 
 
  :  التوقيع 
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Patient No./code:    
Age:  
Sex:     
 Diagnosis:    
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
……… 
Other autoimmune diseases diagnosed for the same patient 
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
……… 
Other inherited autoimmune diseases in family  
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
Notes: 
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
……………………………………………………………………………………… 
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AnnexII 
Patients 
Controls 
sample CT60 AG49 
 
Control CT60 AG49 
1 A/G A/A C1 A/G G/G 
2 A/G A/A C2 A/A A/A 
3 A/G A/A C3 A/G A/A 
4 A/G G/G C4 A/A A/A 
5 A/G G/G C5 G/G G/G 
6 A/G A/A C6 G/G G/G 
7 A/G A/A C7 A/G G/G 
8 G/G G/G C8 A/G A/A 
9 A/G G/G C9 G/G G/G 
10 A/G A/A C10 A/G A/A 
11 A/A G/G C11 A/A G/G 
12 A/G A/A C12 A/G G/G 
13 G/G G/G C13 G/G A/A 
14 A/A A/A C14 A/G A/A 
15 A/G A/A C15 A/A A/A 
16 G/G A/A C16 A/A A/A 
17 G/G A/A C17 A/A A/A 
18 A/A G/G C18 G/G G/G 
19 A/G A/A C19 G/G G/G 
20 A/G G/G C20 G/G G/G 
21 A/G A/A C21 A/G A/A 
22 A/G G/G C22 A/A A/A 
23 A/A A/A C23 G/G A/A 
24 A/A G/G C24 G/G A/A 
25 A/G G/G C25 G/G G/G 
26 A/A G/G C26 G/G G/G 
27 A/G A/A C27 G/G G/G 
28 G/G A/A C28 A/G G/G 
29 G/G G/G C29 G/G A/A 
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30 A/A A/A C30 A/G A/A 
31 A/G G/G C31 A/G A/A 
32 A/G G/G C32 A/G A/A 
33 A/A G/G C33 A/G A/A 
34 G/G G/G C34 G/G A/A 
35 A/G G/G C35 A/A G/G 
36 A/A G/G C36 A/G G/G 
37 A/G G/G C37 A/G G/G 
38 A/A G/G C38 A/A G/G 
39 A/A G/G C39 G/G A/A 
40 G/G G/G C40 A/G G/G 
41 A/G A/A C41 A/G A/A 
42 A/A G/G C42 A/G A/A 
43 A/A G/G C43 G/G A/A 
44 A/A G/G C44 G/G A/A 
45 G/G G/G C45 A/A A/A 
46 A/G G/G C46 A/G A/A 
47 A/G G/G C47 G/G G/G 
48 G/G A/A C48 A/G A/A 
49 A/A A/A C49 A/A G/G 
50 A/G G/G C50 A/G G/G 
51 A/G A/A C51 A/G G/G 
52 A/G G/G C52 A/G A/A 
53 A/A A/A C53 A/G A/A 
54 A/A G/G C54 G/G A/A 
55 A/G A/A C55 A/G A/A 
56 A/A G/G C56 A/G A/A 
57 A/G G/G C57 A/A A/A 
58 G/G A/A C58 A/A A/A 
59 A/G G/G C59 A/G G/G 
60 A/G G/G C60 A/G A/A 
61 A/G A/A C61 G/G A/A 
62 A/G A/A C62 A/G A/A 
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63 G/G G/G C63 A/G A/A 
64 A/G A/A C64 A/A A/A 
65 A/G G/G C65 A/G A/A 
66 A/G G/G C66 A/A A/A 
67 G/G G/G C67 A/G A/A 
68 A/G A/A C68 A/A A/A 
69 A/G G/G C69 A/G A/A 
70 A/A A/A C70 A/G A/A 
71 A/A A/A C71 G/G A/A 
72 A/A G/G C72 A/G A/A 
73 G/G G/G C73 A/A A/A 
74 A/A G/G C74 A/G A/A 
75 A/G A/A C75 A/A A/A 
76 A/A A/A C76 A/G A/A 
77 G/G G/G C77 A/G A/A 
78 A/G G/G C78 A/G A/A 
79 A/G G/G C79 A/G A/A 
80 A/G G/G C80 G/G A/A 
81 A/G G/G C81 A/G A/A 
82 A/G A/A C82  A/A A/A 
83 G/G G/G    
84 A/A A/A    
85 A/G G/G    
86 G/G A/A    
87 A/G G/G    
88 A/A A/A    
89 A/G A/A    
90 A/A A/A    
91 A/G G/G    
92 A/G G/G    
93 A/G G/G    
94 A/G G/G    
95 A/G G/G    
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96 A/G G/G    
97 G/G A/A    
98 G/G A/A    
99 A/G A/A    
100 A/A A/A    
101 A/G G/G    
102 A/G A/A    
103 A/A G/G    
104 G/G G/G    
105 A/G A/A    
106 A/G G/G    
107 A/G G/G    
108 A/G A/A    
109 G/G G/G    
110 G/G G/G    
111 A/A A/A    
112 A/G G/G    
113 G/G G/G    
114 A/G A/A    
115 G/G A/A    
116 A/G G/G    
117 A/G G/G    
118 A/G G/G    
119 G/G G/G    
120 G/G G/G    
 
 
 
 
 
